Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04480554 · ClinicalTrials.gov registry record · Phase 2

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

A Phase 2 study of Opioid Use Disorder and Inflammation, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 2
Development phase
225
Enrollment target
2
Study locations

NCT04480554: Recruiting Phase 2 study of Opioid Use Disorder and Inflammation, sponsored by University of Pennsylvania.

NCT04480554 is a Phase 2 study of Opioid Use Disorder and Inflammation that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 225 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04480554, a Phase 2 study of Opioid Use Disorder and Inflammation, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 2
Development phase
225 participants
Enrollment target
2
Study locations

Study Summary

HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut. The overall objective of this study is to define the impact of long-term mu-opiate receptor stimulation or blockage with medication for opiate use disorder (i.e, methadone, buprenorphine/naloxone, or extended-release naltrexone) on the kinetics and extent of immune reconstitution on HIV-1 infected people who inject opiate and initiating antiretroviral therapy.

Primary Outcome

Change in plasma sCD14 concentration over 24 weeks

Interventions

  • DRUG Methadone
  • DRUG Buprenorphine/naloxone
  • DRUG XR-Naltrexone

Study Locations (2)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Other

  • Go Vap Clinic - Ho Chi Minh City

Trial Details

FieldValue
Enrollment Target 225 participants
Start Date 2023-01-30
Est. Completion 2025-06-30
Phase Phase 2
University of Pennsylvania

1,423 total trials

What NCT04480554 shows while recruiting

NCT04480554 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower).

The record links to 8 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Methadone is the first listed.

NCT04480554 reports a single indexed study location in Pennsylvania, Other.

Frequently Asked Questions

What is clinical trial NCT04480554 about?

NCT04480554 is a clinical study titled "Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1". HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut. The overall objective of this study is to define the impact of long-term mu-opiate receptor stimulation or blockage with medicati...

What is the current status of trial NCT04480554?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2023-01-30. Estimated completion is 2025-06-30.

What conditions does trial NCT04480554 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Inflammation, HIV-1-infection, Buprenorphine, Methadone.

What interventions are being tested in trial NCT04480554?

The interventions under investigation include: Methadone (DRUG), Buprenorphine/naloxone (DRUG), XR-Naltrexone (DRUG).

Who is sponsoring clinical trial NCT04480554?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04480554 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04480554's enrollment target sits among peer trials

225 82nd of 257 higher than 173 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03955445 · 225 participants · Phase 3

    Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

  • NCT04054310 · 225 participants · NA

    Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

  • NCT04888104 · 225 participants

    Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients

  • NCT05190679 · 225 participants

    Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04480554, the US trial registry maintained by the National Library of Medicine. NCT04480554 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.